top of page

Journal of Pharmaceutical Sciences

Outstanding early career scientists for 2022

Immagine 2023-01-18 111802.png

Simone will speak about PBPK and nanoformulation in Seattle 

February 18, 2023

Directly from AAPS 2022 PHARMSCI 360 Boston Convention & Exhibition Center.
Boston, MA

October 16-19, 2022

Unknown.jpeg

Emerging Role of Systems Pharmacology, Long-acting, & Targeted Drug-combination Tech in Making Therapeutic & Health Impact

Monday, October 2022            9-9:30 & 10-10:30 AM

Rethinking the Role of Clinical Pharmacology in a Systems Perspective to Accelerate Small Molecules (Entry, Protease and Polymerase Inhibitors) Development

Monday, October 17, 2022        3:45 PM – 4:00 PM

aaaaaaaaaa.png

Two years anniversary from our President Interview at TG Leonardo in Italy. Those days marked the start of the pandemic. The interview had great relevance in Italy where it got more than 2 million view.

https://www.youtube.com/watch?v=7BpQthHGU0I

March 9th, 2022

Pharmacokinetics, Pharmacodynamics and Drug Transport and Metabolism
 

Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 2: Model for the Drug-combination Nanoparticles.
 

https://www.sciencedirect.com/science/article/pii/S0022354921005529?dgcid=coauthor

January 31th, 2022

Pharmacokinetics, Pharmacodynamics and Drug Transport and Metabolism
 

Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 1: Model for the Free-Drug Mixture
 

https://www.sciencedirect.com/science/article/abs/pii/S0022354921005475?dgcid=coauthor

December 9th, 2021

Here an example of what we can offer. FDA Approves a New Dose of #INGREZZA (#Valbenazine) for Treatm. 
The development program for this sNDA was facilitated via meetings under the Prescription Drug User Fee Act (PDUFA) VI Model-Informed Drug Development (MIDD) Paired Meeting Pilot Program. MIDD is an approach that involves developing and applying exposure-based, biological, and statistical models derived from preclinical and clinical data sources to inform drug development and decision-making. It aims to integrate information from diverse data sources to help decrease uncertainty and lower failure rates and to develop information that cannot or would not be generated experimentally. For additional information on the MIDD Paired Meeting Pilot Program, please visit https://go.usa.gov/xdtdP.



May 21th, 2021
 

2020-12-10-covid-hero-graphicv2.jpeg

Supporting the Development of Long-acting HIV Injectables via Pharmacokinetic Modeling.


Simone Perazzolo UW Pharmaceutics Research Associate in the Rodney Ho Lab, will be presenting on his research,

“Supporting the Development of Long-acting HIV Injectables via Pharmacokinetic Modeling.”

(Abstract attached) 

 

 



November 9th, 2020
 

image004.png

UW Pharmaceutics engineer discusses how HIV research could impact COVID-19 remendis











Rai Italyt Tg3 March 12th, 2020

bottom of page